Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Backs Imbruvica In CLL On Price Cut Despite Outcome Uncertainties

Executive Summary

It looks likely AbbVie. and Johnson & Johnson's Imbruvica (ibrutinib) will be made routinely available on the NHS in England and Wales for treating chronic lymphocytic leukemia after an undisclosed price cut was offered and data further considered by the UK HTA NICE.

Advertisement

Related Content

Imbruvica Gets Broad CLL Okay in EU But Draft Rebuff From UK's NICE

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel